Neukio Biotherapeutics on a New Mission
Quality-based
Specification-oriented
Patient-centered
Building new future in cell therapy
About Neukio
Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis, through internal discovery and external collaboration, with emphasis on innovative immuno-oncology products.
90
million dollars raised of financing
2021
Corporate established
5700
square meters of R&D and manufacturing facilities
NK Cell
Natural killer (NK) cells are key players in our immune system. Derived from bone marrow lymphoid stemcells, NK cells are mainly distributed in bone marrow, peripheral blood, liver, spleen, lung, and lymph nodes. Unlike T- and B-lymphocytes, NK cells can recognize and kill a broad spectrum of ‘non-self’ cells, including tumor cells and virally infected cells, without the need for pre-immune activation or sensitization.
Allogenic
Commercial production
Solid tumor
News
-442.jpg)
Press Releases
About Founder
Richard Liqun Wang Ph. D., MBA.
Founder, Chairman and CEO， Neukio Biotherapeutics
Former positions held：
- VP & CTO, Fosun Pharma
- Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first CAR-T product) in less than three years
- COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies
- Head of Operations, GSK R&D Center in China
- Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China
- Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA
- Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USA
WELCOME ABOARD
